Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

NCT03382262 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis of the Shoulder
Osteoarthritis of the Hip

Interventions

DRUG: FX006 32 mg
DRUG: TAcs 40 mg

Sponsor

Pacira Pharmaceuticals, Inc